What is Amarantus BioScience Holdings?
Amarantus BioScience Holdings (AMBS) operates as a specialized biotechnology holding company with a focus on orphan neurologic, regenerative medicine, and ophthalmic therapies. Through its strategic subsidiaries, the firm manages a robust intellectual property portfolio, including the development of eltoprazine for Parkinson's disease and ADHD, as well as the Engineered Skin Substitute (ESS) technology for severe pediatric burns. Central to its innovation strategy is the PhenoGuard discovery engine, which has facilitated the identification of the therapeutic protein MANF. By leveraging these proprietary assets, Amarantus aims to address significant unmet medical needs in neurodegenerative and dermatological conditions, positioning itself as a key player in the high-growth regenerative medicine sector.
How much funding has Amarantus BioScience Holdings raised?
Amarantus BioScience Holdings has raised a total of $17.2M across 9 funding rounds:
Other Financing Round
$1.1M
Multiple Rounds
$4.3M
Share Placement
$5M
Private Equity
$2.8M
Private Equity
$1M
Share Placement
$3M
Other Financing Round
$100K
Other Financing Round (2012): $1.1M with participation from Undisclosed
Private Equity (2013): $1.3M, investors not publicly disclosed
Debt (2013): $1.4M, investors not publicly disclosed
Private Equity (2013): $1.6M featuring International Infusion and Dominion Capital
Share Placement (2015): $5M backed by Discover Growth Fund
Private Equity (2015): $2.8M, investors not publicly disclosed
Private Equity (2016): $1M led by International Infusion, LLC
Share Placement (2016): $3M, investors not publicly disclosed
Other Financing Round (2017): $100K featuring XPress Group International
Key Investors in Amarantus BioScience Holdings
International Infusion, LLC
A venture capital firm focused on disruptive technologies within the life sciences and renewable energy sectors, aiming to solve global challenges through innovative force multipliers.
Dominion Capital
A major energy utility and investment entity that supports infrastructure assets, grid modernization, and clean energy initiatives, often backing projects with significant long-term economic and environmental impact.
Discover Growth Fund
An investment vehicle specializing in identifying and scaling high-potential growth companies, providing the necessary capital to bridge the gap between research and commercial viability.
What's next for Amarantus BioScience Holdings?
With the recent capital injection, Amarantus BioScience Holdings is well-positioned to accelerate its clinical trial timelines and expand its research capabilities. The strategic focus will likely shift toward the execution of pivotal studies for its ESS technology and the advancement of MANF-based products through regulatory milestones. As the company matures, the integration of its subsidiary assets and the potential for further licensing agreements will be paramount in driving long-term shareholder value. The firm's ability to maintain its momentum in the orphan drug market will depend on its success in navigating the complex regulatory environment while continuing to leverage its proprietary discovery platform to identify future therapeutic candidates.
See full Amarantus BioScience Holdings company page
